

China's CanSinoBIO obtains approval for clinical trials on inhaled TB vaccine in Indonesia

19 May 2025 | News

For stronger immune responses in the respiratory tract and the lungs



CanSino Biologics Inc, based in China, has obtained clinical trial approval from the Badan Pengawas Obat dan Makanan, Republik Indonesia to initiate a clinical trial for its Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector) (the inhaled TB Booster).

Currently, the traditional Bacillus Calmette-Guerin vaccine (BCG vaccine), also the only available tuberculosis vaccine in the world, is typically administered at birth. Additionally, the BCG vaccine declines over time and cannot enhance vaccine protection through booster doses, resulting in limited protection for adults. To address this deficiency, the inhaled TB vaccine is the first generation of a globally innovative tuberculosis booster vaccine for the BCG vaccine.

The inhaled TB Booster is designed to be administered via inhalation, inducing stronger immune responses in the respiratory tract and the lungs, the primary site of tuberculosis infection. This needle-free delivery method aims to clear tuberculosis bacilli and control latent infection, potentially achieving the effect of preventing infections and marking a breakthrough in tuberculosis prevention.

The Phase Ia and Phase Ib clinical trials for TB Booster were completed in Canada, and the clinical trial data demonstrated its safety and its effectiveness as a booster for BCG vaccine, as well as its superiority of mucosal immunity. The upcoming clinical trial in Indonesia will assess the inhaled TB Booster's safety and immunogenicity of a single dose in adults aged 18 to

49 years.